JAMA has a couple of interesting research letters regarding uptake of biosimilars.
Read More
Today, we hear from the PBM trade association, pointing (or giving) the finger at medication makers for high prices.
In the frenzy over drug prices, all sides are releasing studies on who is to blame. Here is one sponsored by the drug manufacturers’ trade association.
An analysis published in JAMA finds that Medicare is wasting about a billion dollars a year purchasing brand-name drugs.
The most recent Government Accounting Office report on the 340B drug purchase program illustrates just how bad hospital abuse of it is.
Its not really shocking, but depressingly expected for drug companies to screw the public by preventing competition.
New “precision” medicines are being approved with fewer and small trials, which may raise safety questions.
The annual report on drug spending in the United States from the former IMS Institute, now IQVIA, has been released, showing a welcome moderation in growth.
A Milliman brief supported by the drug industry gives more examples of the ills of the 340B drug purchase program.
Research in the British Journal of Medicine Quality & Safety examines physician reactions to medication alerts from clinical health information systems.
An article in the New England Journal of Medicine reviews the consequences of the 340B drug program.
Express Scripts releases its Drug Trend Report for 2017, showing muted growth.
A report from Accenture describes results from a survey of patient preferences regarding medical products.
You may have seen some stories about how drug manufacturers have been exercising “restraint” in keeping their 2018 price increases under 10%. This makes me sick. These companies are raising prices with absolutely no cost justification, this is purely generating higher profits. They should be pilloried, not lauded.
A survey of large employers confirms significant dissatisfaction with PBM relationships.
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Apple Podcasts
Google Podcasts
Spotify
Overcast
PocketCasts
Radio Public
Stitcher
Anchor
RSS - Posts